Thrombophilia prevalence among women with placenta‐mediated pregnancy complications

Gils, Charlotte; Nybo, Mads

doi:10.1016/j.ijgo.2015.12.007

Cited by 3 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Placenta-mediated pregnancy complications (PMPC) such as preeclampsia, intrauterine growth restriction (IUGR), birth of a small-for gestational age infant, obstetric morbidity and recurrent pregnancy loss, stillbirth or placental abruption, are significant causes of maternal and fetal poor outcome [1]. These complications are believed to result due to thrombophilia, and therefore from thrombosis within the placental angioarchitecture [1][2][3].…”

mentioning

confidence: 99%

“…All authors have contributed equally to this paper encode coagulation factor V (Leiden mutation, G1691A) or coagulation factor II (mutation G20210A) [1,5,9]. The most commonly acquired maternal thrombophilia is the obstetric antiphospholipid syndrome (OAPS) defined as the association of thrombotic events or obstetric morbidity in patients persistently positive for antiphospholipid antibodies (aPL) [1,10,11].…”

mentioning

confidence: 99%

“…Furthermore, hyperhomocysteinemia, which can be hereditary or acquired, is a risk factor for diseases that primarily affect the arteries [1,12].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Maternal-Fetal Management in Trombophilia Related and Placenta-Mediated Pregnancy Complications

Berceanu¹,

Ciurea²,

Cîrstoiu³

et al. 2018

Rev. Chim.

View full text Add to dashboard Cite

It is widely accepted that thrombophilia in pregnancy greatly increases the risk of venous thromboembolism. Pregnancy complications arise, at least partly, from placental insufficiency. Any change in the functioning of the gestational transient biological system, such as inherited or acquired thrombophilia, might lead to placental insufficiency. In this research we included 64 pregnant women with trombophilia and 70 cases non-trombophilic pregnant women, with or without PMPC, over a two-year period. The purpose of this multicenter case-control study is to analyze the maternal-fetal management options in obstetric thrombophilia, the impact of this pathology on the placental structure and possible correlations with placenta-mediated pregnancy complications. Maternal-fetal management in obstetric thrombophilia means preconceptional or early diagnosis, prevention of pregnancy morbidity, specific therapy as quickly as possible and fetal systematic surveilance to identify the possible occurrence of placenta-mediated pregnancy complications.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Maternal-Fetal Management in Trombophilia Related and Placenta-Mediated Pregnancy Complications

Berceanu¹,

Ciurea²,

Cîrstoiu³

et al. 2018

Rev. Chim.

View full text Add to dashboard Cite

show abstract

“…However, the evidence thus far is not conclusive, and there is much confusion regarding the role of heparins in the prevention of PMPC. Moreover, the significant association between inherited thrombophilia and the development of PMPC is under debate, since not all patients with inherited thrombophilia develop PMPC, and most patients with PMPC screen negative for inherited thrombophilia (41)(42)(43)(44)(45). Therefore, we conducted a systematic review and metaanalysis aimed at answering the question: are LMWHs effective in the secondary prevention of placental mediated obstetrical syndromes in non thrombophilic pregnant women?…”

Section: Introductionmentioning

confidence: 99%

LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia

Mastrolia¹,

Novack²,

Thachil³

et al. 2016

Thromb Haemost

View full text Add to dashboard Cite

Placental mediated pregnancy complications such as preeclampsia and fetal growth restriction (FGR) are common, serious, and associated with increased morbidity and mortality. We conducted a systematic review and meta-analysis to determine the effect of treatment with low-molecular-weight heparins (LMWHs) for secondary prevention of these complications in non thrombophilic women. We searched the electronic databases PubMed, Scopus, and Cochrane Library for randomised controlled trials addressing this question. Five studies including 403 patients met the inclusion criteria, 68 developed preeclampsia and 118 FGR. The studies were very heterogeneous in terms of inclusion criteria, LMWH preparation, and dosage. Meta-analyses were performed using random-effect models. The overall use of LMWHs was associated with a risk reduction for preeclampsia (Relative risk (RR) 0.366; 95 % confidence interval (CI), 0.219-0.614) and FGR (RR 0.409; 95 % CI, 0.195-0.932) vs. no treatment. From the data available for analysis it appears that the use of Dalteparin is associated with a risk reduction for preeclampsia (p=0.002) and FGR (p<0.001); while Enoxaparin is associated with risk reduction for preeclampsia (p=0.013) but not for FGR (p=0.3). In spite of the small number of studies addressing the research question, and the high variability among them, our meta-analysis found a modest beneficial effect of LMWH for secondary prevention of preeclampsia and FGR. Further studies are needed to address these questions before a definite conclusion can be reached.

show abstract

Placenta-mediated pregnancy complications are not associated with fetal or paternal factor V Leiden mutation

Nevalainen

Ignatius

Savolainen

et al. 2018

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Thrombophilia prevalence among women with placenta‐mediated pregnancy complications

Cited by 3 publications

References 21 publications

Maternal-Fetal Management in Trombophilia Related and Placenta-Mediated Pregnancy Complications

Maternal-Fetal Management in Trombophilia Related and Placenta-Mediated Pregnancy Complications

LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia

Placenta-mediated pregnancy complications are not associated with fetal or paternal factor V Leiden mutation

Contact Info

Product

Resources

About